Cellares stock $3.10 USD
Private-market facts for current and former Cellares employees researching their stock.
Price per share sourced from public secondary-market data. Updated April 2026. Indicative only — not a live quote.
Overview
Cellares builds the Cell Shuttle, a fully automated, end-to-end cell therapy manufacturing platform that dramatically reduces the time, cost, and manual labor required to produce personalized cell therapies.
Cellares outlook
For employees evaluating Cellares equity, a 1x base multiple suggests the stock may be close to fairly valued at current prices.
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling Cellares shares
Why shareholders consider selling
Shareholders in Cellares may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Cellares does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Cellares stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Cellares shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Cellares shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series B round and recent secondary-market pricing can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Cellares shareholders
Exploring equity in Cellares often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Cellares most recently raised a Series B round . Total funding raised to date is approximately $255M.
Lead investors in this round include Eclipse Ventures and Lux Capital.
Founders & company background
Cellares was founded in 2019 by Fabian Gerlinghaus, Aparna Rishi, Alex Schmitz and is headquartered in South San Francisco, CA.
Investors
Industry
Similar private companies
Latest Cellares news
Frequently asked questions
- Is Cellares still a private company?
- Yes, Cellares is currently a private company.
- What is Cellares's latest funding round?
- Cellares's most recent known round is Series B.
- What is Cellares's valuation?
- Cellares's valuation has not been publicly disclosed.
- Who are the investors in Cellares?
- Notable investors include Eclipse Ventures, Lux Capital, EcoR1 Capital.
- Can I sell my Cellares stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Cellares stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Cellares data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.